Medicare AdvantageCoverageMedium impact
MA08.016h, Treatment of Pulmonary Artery Hypertension with Intravenous, Subcutaneous, and Inhaled Pharmacologic Agents
Independence Blue Cross·Pulmonology, Cardiology, Critical Care·Pharmacy
Effective date
Apr 1, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.016h for treatment of pulmonary artery hypertension with IV, subcutaneous, and inhaled medications has been reissued and will take effect April 1, 2026. This policy governs coverage and authorization requirements for specialized PAH treatments.
Action Required
Before April 1, 2026: Review updated policy MA08.016h at the provided URL to identify any changes to prior authorization requirements, coverage criteria, or documentation standards for pulmonary artery hypertension treatments. Update billing protocols and staff training for IV, subcutaneous, and inhaled PAH medications accordingly.